
ONCOHELIM

Testing site & Shipping Address:

Hematology Translational Lab (HTL)

PATIENT INFORMATION					
Name (Last, First)					
Medical Record #					
Date of Birth (YYYY/MM/DD): Gender: M F					
Address:City:					
Prov./State: Country:					
Prov./ State Country Postal/Zip code					

	ospital Drive NW, Calga		Address:		City:	
Phone: +1(403)220- Fax: +1(403)210-817		Prov./State: Country:				
		ORDER	INFORMATION			
Requesting Physician			Location/Facility			
Address		City				
Phone	Fax	Email			Report delivery method: Email Fax	
		D	IAGNOSIS			
Solid Tumor Type i.e., Lung (NSCLC)		Cancer State YES	us: Metastatic NO Other details: i.e., known genomic variant			
		TES	ST REQUEST			
		SOLID TUMO	OR GENOMIC PANELS	5		
OncoHelix-1 324 genes CGP Pane	el (Tissue: DNA)	CGP Assay uses the Roc which leverages a secon FoundationOne® Analy	ndary process, the		SNVs & Indels: 306 cancer-related genes (DN Fusions: 36 genes (DNA); CNV: 59 targets MSI and TMB	NA)
OncoHelix-2 170 genes CGP Pane	el (Tissue: DNA and RNA)	CGP Assay uses the Illu i *see pg3 for details	mina TST-170 panel	SNVs & Indels: 133 cancer-related genes (DN Fusions: 55 genes (RNA); CNV: 59 targets	NA)	
OncoHelix-3 170 genes CGP Pane	el (Tissue: DNA only)	CGP Assay uses the Illu i panel) *see pg3 for detail		SNVs & Indels: 133 cancer-related genes (DN Fusions: NO fusions genes; CNV: 59 targets		
OncoHelix-4 38 genes – ctDNA pa	Assay uses FOLLOW IT® ctDNA Liquid Biopsy Focused Panel (Blood: DNA) Assay uses FOLLOW IT® ctDNA Liquid Biopsy Focused CNV: 9 targets					
		SELF-PA	YMENT DETAILS			
Contact Name: Patient	or patient support person	Email: (Required)			Phone:	
Contact Name: Patient	or patient support person	Email: (Required)	ΛΕΝ RETRIEVAL		Phone: report included with TRF (Require	ed)
	or patient support person	Email: (Required) SPECIN	<u> </u>] <u>Path</u>		<u>ed)</u>
	ontact Pathology Lab to o	Email: (Required) SPECIN	<u> </u>] <u>Path</u>	report included with TRF (Require	<u>ed)</u>
OncoHelix can co	ontact Pathology Lab to o	Email: (Required) SPECIN	Cancer Clinic w	Path	report included with TRF (Require	<u>ed)</u>
OncoHelix can co	ontact Pathology Lab to o	SPECINO SPECINO SPECINO SPECIMENT SP	Cancer Clinic w	Path vill arrange t	report included with TRF (Require he specimen shipment Fax:	ed)
OncoHelix can co Pathologist Name: Specimen ID: I certify that I am the pand purpose of testing herein, (b) retain de-id	ontact Pathology Lab to o	SPECINO SPECINO SPECINO SPECINO SPECINO SPECINO SPECIMEN SPECIMEN SPECIMEN SITE: TEST AUTHORIZATION and that results from this total sed informed consent, sired or permitted by law for the sed in t	Cancer Clinic w Phone: ON, CONSENT & SIGN est/s may inform the pato the extent legally refor internal quality assu	Path vill arrange t Date of Co ATURES atient's ongo quired, to pe rance/operat	report included with TRF (Require he specimen shipment Fax: collection (YY/MM/DD): ling/future treatment. I have explained the natural oncoHelix to (a) perform the test/s specitional improvement, (c) use/disclose de-identifications.	ture
OncoHelix can co Pathologist Name: Specimen ID: I certify that I am the pand purpose of testing herein, (b) retain de-id	patient's treating physician of the patient and have obtained test results as requatient information) results a	SPECINO SPECINO SPECINO SPECINO SPECINO SPECINO SPECIMEN SPECIMEN SPECIMEN SITE: TEST AUTHORIZATION and that results from this total sed informed consent, sired or permitted by law for the sed in t	Cancer Clinic w Phone: ON, CONSENT & SIGN est/s may inform the part of the extent legally refor internal quality assu going/future unspecifie	Path vill arrange t Date of Co ATURES atient's ongo quired, to pe rance/operat	report included with TRF (Require he specimen shipment Fax: collection (YY/MM/DD): ling/future treatment. I have explained the natural oncoHelix to (a) perform the test/s specitional improvement, (c) use/disclose de-identifications.	ture
OncoHelix can co Pathologist Name: Specimen ID: I certify that I am the pand purpose of testing herein, (b) retain de-id (without identifiable pathons of the company of t	patient's treating physician as to the patient and have obtained test results as requatient information) results a signature partner lab HTL to (a) perfects and clinical interpretation	SPECINO SPECINO SPECINO SPECINO SPECINO SPECINO SPECINO SPECIMEN SITE: Specimen Site: TEST AUTHORIZATION SPECIMEN SITE SPECIMEN SITE SPECIMEN SITE SPECIMEN SITE SPECIMEN SP	Cancer Clinic w Phone: ON, CONSENT & SIGN est/s may inform the part of the extent legally refor internal quality assured going/future unspecified min Canada (b) retain the research or to improve	Path vill arrange t Date of Co ATURES atient's ongo quired, to pe rance/operat ed research are e de-identified test results as	report included with TRF (Require he specimen shipment Fax: bllection (YY/MM/DD): ing/future treatment. I have explained the natural concoller of the concol	ture fied fied e of
OncoHelix can co Pathologist Name: Specimen ID: I certify that I am the pand purpose of testing herein, (b) retain de-id (without identifiable pathonic ordering Physici I permit OncoHelix & Canada with final analyassurance/operational sequencing data for on	patient's treating physician as to the patient and have obtained test results as requatient information) results a signature partner lab HTL to (a) perfeysis and clinical interpretation improvement, reporting,	SPECING SPECING SPECING SPECING SPECING SPECING SPECING SPECIMEN SITE: Specimen Site: TEST AUTHORIZATION SPECIMEN SITE SPECIMEN SITE SPECIMEN SITE SPECIMEN SPECIME	Cancer Clinic w Phone: ON, CONSENT & SIGN est/s may inform the property of the extent legally refor internal quality assured going/future unspecified me erein, that may include me in Canada (b) retain the research or to improve ourposes.	Path vill arrange t Date of Co ATURES atient's ongo quired, to pe rance/operat ed research are e de-identified test results as	report included with TRF (Require he specimen shipment Fax: collection (YY/MM/DD): ing/future treatment. I have explained the natural oncoHelix to (a) perform the test/s specitional improvement, (c) use/disclose de-identified development purposes. Date d sequencing data analysis performed outsides required or permitted by law for internal quality.	ture fied fied e of
OncoHelix can co Pathologist Name: Specimen ID: I certify that I am the pand purpose of testing herein, (b) retain de-id (without identifiable pathonic ordering Physici I permit OncoHelix & Canada with final analyassurance/operational sequencing data for on	patient's treating physician as to the patient and have obtained information attention	SPECIAL SPECIA	Cancer Clinic w Phone: ON, CONSENT & SIGN est/s may inform the property of the extent legally refor internal quality assured going/future unspecified me erein, that may include me in Canada (b) retain the research or to improve ourposes.	Path vill arrange t Date of Co ATURES atient's ongo quired, to pe rance/operat ed research are e de-identified test results as	report included with TRF (Require he specimen shipment Fax: collection (YY/MM/DD): ing/future treatment. I have explained the natural oncoHelix to (a) perform the test/s specitional improvement, (c) use/disclose de-identified development purposes. Date disequencing data analysis performed outsides required or permitted by law for internal quality mand (c) use/disclose de-identified results	ture fied fied e of
OncoHelix can co Pathologist Name: Specimen ID: I certify that I am the pand purpose of testing herein, (b) retain de-id (without identifiable pathonic ordering Physici I permit OncoHelix & Canada with final analyassurance/operational sequencing data for on	patient's treating physician as to the patient and have obtained test results as requatient information) results a signature partner lab HTL to (a) perfeysis and clinical interpretation improvement, reporting, agoing/future unspecified results are considered to the constant of the cons	SPECIAL SPECIA	Cancer Clinic w Phone: ON, CONSENT & SIGN est/s may inform the property of the extent legally refor internal quality assured going/future unspecified min Canada (b) retain the research or to improve ourposes. The internal quality assured in Canada (b) retain the research or to improve ourposes.	Path vill arrange t Date of Co ATURES atient's ongo quired, to pe rance/operated research and et de-identifie etest results as et the progra	report included with TRF (Require he specimen shipment Fax: collection (YY/MM/DD): ing/future treatment. I have explained the natural oncoHelix to (a) perform the test/s specitional improvement, (c) use/disclose de-identified development purposes. Date disequencing data analysis performed outsides required or permitted by law for internal quality mand (c) use/disclose de-identified results	ture fied fied e of





SAMPLE REQUIREMENT & GUIDELINES

	SAMPLE REQUIREMENT & GUIDELINES							
Nucleic Acid and Tissue for Solid Tumor Genomic Analysis Panels								
Panel	DNA	RNA	Biopsy	FFPE	Blood	Gu	uidelines for 35 to 306+ gene panels	
OncoHelix-1 324 genes CGP Panel			120 μm or 4 mm ³			paraffin embed	racted nucleic acids and fresh frozen (FF) or formalin fixed fin embedded (FFPE) tissue samples are accepted	
OncoHelix-2 170 genes CGP Panel	250 ng	150 ng				• 120 µm of FFPE tissue section (4 scrolls of 30 µm thickness) with a minimum of 40% tissue content & 20% tumor cellularity*; or 2-4 FFPE cores of 1-2 mm³; or 4 mm³ FF tissue. For		
OncoHelix-3 170 genes CGP Panel							DNA only panels, the requirements are reduced to half Please call HTL lab if tumour cellularity is <20% and ≥10%	
OncoHelix-4 38 genes – ctDNA panel	✓				✓		or: 2 Streck blood tubes collected within 14 days of off to HTL genomic diagnostic lab	
Specimen Type (select all that apply) Biopsy Type: FFPE Tissue Blood Other (specify)								
 General Notes and Quality Recommendations: Minimum required nucleic acid concentrations are based on fluorometric estimation with Qubit reagents. A spectrophotometric method (nanodrop) overestimates the amount of nucleic acid and may only be used for the determination of sample purity (260/280 ≥ 1.8 for DNA and ≥ 1.9 for RNA) Nucleic must acid be extracted from a minimum of 1 ml of biopsy in EDTA, 120 μm or of FFPE tissue or 4 mm³ of FF tissue All nucleic acids will be tested for quality as per laboratory thresholds prior to processing For FF tissue, samples must be flash-frozen in liquid nitrogen as quickly as possible after removal from patients and immediately delivered to the laboratory. Samples must be kept in −80°C freezers until DNA and RNA extraction For both FF and FFPE samples, H&E slides must be analyzed by the pathologist and estimation of tumor cellularity must be provided 							imates	
SPECIMEN TYPE SHIPPING & HANDLING INSTRUCTIONS REJECTION CRITERIA								
DNA & RNA FF Tissue		 Ship at -20°C (use dry ice) DNA only specimens may be shipped at 4 °C 			boptimal quantity/quality PE/FF: Tissue content < 40%; Tumor cellularity < 20%	6		
FFPE Tissue	• Sh	Ship at room temperature						
2 Blood Streck Tubes	2 Blood Streck Tubes • Ship at room temperature • Collected > 14 days ago							
CHECKLIST								
A completed requisition has been sent with the specimen/s A pathology report has been sent with the specimen/s Any available genomic (single gene or panel) profile report/s has been sent with the specimen/s								
Please provide the following information:								
Tissue content:			Tumor cell	ularity:			Pathologist's Name:	

Shipping Address	For HTL Laboratory Use Only
ATTN: Dr. Faisal Khan Hematology Translational Lab (HTL) HMRB 336, 3330, Hospital Drive NW, Calgary, AB, CANADA T2N 4N1	Sample Received(YYYY-MM-DD)(AM/PM) Specimen type



SOLID TUMOR NGS PANEL DESCRIPTION

OncoHelix-1: 324 genes CGP Panel

CGP Assay uses the Roche AVENIO Tumor Tissue CGP Kit, which leverages a secondary process, the FoundationOne® Analysis Platform*

Specimen compatibility: Genomic DNA extracted from fresh frozen and FFPE tissues

Small variants (306): ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, ALOX12B, AMER1, APC, AR, ARAF, ARFRP1, ARID1A, ASXL1, ATM, ATR, ATRX, AURKA, AURKB, AXIN1, AXL, BAP1, BARD1, BCL2, BCL2L1, BCL2L2, BCL6, BCOR, BCORL1, BRAF, BRCA1, BRCA2, BRD4, BRIP1, BTG1, BTG2, BTK, C11orf30, CALR, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCND3, CCNE1, CD22, CD274, CD70, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B, CDKN2A, CDKN2B, CDKN2C, CEBPA, CHEK1, CHEK2, CIC, CREBBP, CRKL, CSF1R, CSF3R, CTCF, CTNNA1, CTNNB1, CUL3, CUL4A, CXCR4, CYP17A1, DAXX, DDR1, DDR2, DIS3, DNMT3A, DOT1L, EED, EGFR, EP300, EPHA3, EPHB1, EPHB4, ERBB2, ERBB3, ERBB4, ERCC4, ERG, ERRFI1, ESR1, EZH2, FAM46C, FANCA, FANCC, FANCG, FANCL, FAS, FBXW7, FGF10, FGF12, FGF14, FGF13, FGF3, FGF4, FGF6, FGFR1, FGFR2, FGFR3, FGFR4, FH, FLCN, FLT3, FOXL2, FUBP1, GABRA6, GATA3, GATA4, GATA6, GID4 (C17orf39), GNA11, GNA13, GNAQ, GNAS, GRM3, GSK3B, H3F3A, HDAC1, HGF, HNF1A, HRAS, HSD3B1, ID3, IDH1, IDH2, IGF1R, IKBKE, IKZF1, INPP4B, IRF2, IRF4, IRS2, JAK1, JAK2, JAK3, JUN, KDM5A, KDM5C, KDM6A, KDR, KEAP1, KEL, KIT, KLHL6, KMT2A (MLL), KMT2D (MLL2), KRAS, LTK, LYN, MAF, MAP2K1, MAP2K2, MAP2K4, MAP3K1, MAP3K13, MAPK1, MCL1, MDM2, MDM4, MED12, MEF2B, MEN1, MERTK, MET, MITF, MKNK1, MLH1, MPL, MRE11A, MSH2, MSH3, MSH6, MST1R, MTAP, MTOP, MUTYH, MYC, MYCL, MYCN, MYD88, NBN, NF1, NF2, NFE2L2, NFKBIA, NKX2-1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NT5C2, NTRK1, NTRK2, NTRK3, P2RY8, PALB2, PARK2, PARP1, PARP2, PARP3, PAX5, PBRM1, PDCD1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C3B, PIK3C3G, PIK3CA, PIK3CB, PIK3R1, PIM1, PMS2, POLD1, POLE, PPARG, PPP2R1A, PPD2R2A, PRDM1, PRKAR1A, PRKCI, PTCH1, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51B, RAD51C, RAD51D, RAD51D, PRARG, PPP2R1A, PPP2R2A, PRDM1, PRKAR1A, PRKCI, PTCH1, PTEN, PTPN11, PTPRO, QKI, RAC1, RAD21, RAD51B, RAD51C, RAD51D, R RAD52, RAD54L, RAF1, RARA, RB1, RBM10, REL, RET, RICTOR, RNF43, ROS1, RPTOR, SDHA, SDHB, SDHC, SDHD, SETD2, SF3B1, SGK1, SMAD2, SMAD4, SMARCA4, SMARCB1, SMO, SNCAIP, SOCS1, SOX2, SOX9, SPEN, SPOP, SRC, STAG2, STAT3, STK11, SYK, TBX3, TEK, TET2, TIPARP, TNFAIP3, TNFRSF14, TP53, TSC1, TSC2, TYRO3, U2AF1, VEGFA, VHL, WHSC1, WHSC1L1, WT1, XPO1, XRCC2, ZNF217, ZNF703:

RNA fusion (36): ALK, BCL2, BCR, BRAF, BRCA1, BRCA2, CD74, EGFR, ETV4, ETV5, ETV6, EWSR1, EZR, FGFR1, FGFR2, FGFR3, KIT, KMT2A (MLL), MSH2, MYB, MYC, NOTCH2, NTRK1, NTRK2, NUTM1, PDGFRA, RAF1, RARA, RET, ROS1, RSPO2, SDC4, SLC34A2, TERC, TERT, TMPRSS2

*OncoHelix-1: 324 Gene CGP Panel uses the Roche AVENIO Tumor Tissue CGP Kit, which leverages a secondary process, the FoundationOne® Analysis Platform, to provide comprehensive genomic profiling. The research use only assay was validated and its performance characteristics were determined by OncoHelix and its partner lab -Hematology Translational Lab. The panel is not approved by Health Canada, as is the case for all cancer genomic panel. Both OncoHelix and HTL laboratories are clinically accredited by CPSA to perform high-complexity molecular testing. Any decisions related to patient care and treatment choices should be based on the independent judgement of the treating physician. For more information on the AVENIO Tumour Tissue CGP kit matched content of the 324 gene FoundationOne® CDx panel https://sequencing.roche.com/us/en/products/group/avenio-tumor-tissue-cgp-kit.html

OncoHelix-2/3: 170 genes CGP Panel (DNA +/- RNA)

CGP Assay uses Illumina TST-170 panel*

Specimen compatibility: Genomic DNA & RNA extracted from fresh frozen and FFPE tissues

Small variants and indel (148): AKT1, AKT2, AKT3, ALK, APC, AR, ARID1A, ATM, ATR, BAP1, BARD1, BCL2, BCL6, BRAF, BRCA2, BRIP1, BTK, CARD11, CCND2, CC CCNE1, CD79A, CD79B, CDH1, CDK12, CDK4, CDK6, CDKN2A, CEBPA, CHEK1, CHEK2, CREBBP, CSF1R, CTNNB1, DDR2, DNMT3A, EGFR, EP300, ERBB2, ERBB3, ERBB4, ERCC1, ERG, ESR1, EZH2, FAM175A, FANCI, FANCI, FBXW7, FGF1, FGF10, FGF2, FGF3, FGF3, FGF4, FGF5, FGF7, FGF9, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FOXL2, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, INPP4B, JAK2, JAK3, KDR, KIT, KRAS, MAP2K1, MAP2K2, MCL1, MDM2, MDM4, MET, MLH1, MLLT3, MPL, MRE11A, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCN, MYD88, NBN, NF1, NOTCH1, NOTCH2, NOTCH3, NPM1, NRAS, NRG1, PALB2, PDGFRB, PIK3CA, PIK3CB, PIK3CB, PIK3CG, PIK3CG, PIK3CB, PI PTEN, PTPN11, RAD51B, RAD51C, RAD54L, RB1, RET, RICTOR, ROS1, SLX4, SMAD4, SMARCB1, SMO, STK11, TET2, TP53, TSC1, TSC2. DNA amplification target genes (59): AKT2, ALK, AR, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND3, CCNE1, CDK4, CDK6, CHEK1, CHEK2, EGFR, ERBB2, ERBB3, ERCC1, ERCC2, ESR1, FGF10, FGF10, FGF19, FGF2, FGF23, FGF3, FGF4, FGF5, FGF6, FGF7, FGF8, FGF7, FGFR1, FGFR2, FGFR3, FGFR4, JAK2, KIT, KRAS, LAMP1, MDM2, MDM4, MET, MYC, MYCL1, MYCN, NRAS, NRG1, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PTEN, RAF1, RET, RICTOR, RPS6KB1, TFR. RNA fusion target genes (55): ABL1, AKT3, ALK, AR, AXL, BCL2, BRAF, BRCA1, BRCA2, CDK4, CSF1R, EGFR, EML4, ERBB2, ERG, ESR1, ETS1, ETV1, ETV4, ETV5, EWSR1, FGFR1, FGFR2, FGFR3, FGFR4, FLI1, FLT1, FLT3, JAK2, KDR, KIF5B, KIT, KMT2A (MLL), MET, MLLT3, MSH2, MYC, NOTCH1, NOTCH2, NOTCH3, NRG1, NTRK1, NTRK2, NTRK3, PAX3, PAX7, PDGFRA, PDGFRB, PIK3CA, PPARG, RAF1, RET, ROS1, RPS6KB1, TMPRSS2

*OncoHelix-2/3: 170 Gene CGP Panel uses the Illumina TST170 to provide comprehensive genomic profiling. The research use only assay was validated and its performance characteristics were determined by OncoHelix and its partner lab - Hematology Translational Lab. The panel is not approved by Health Canada, as is the case for all cancer genomic panel. Both OncoHelix and HTL laboratories are clinically accredited by CPSA to perform high-complexity molecular testing. Any decisions related to patient care and treatment choices should be based on the independent judgement of the treating physician

OncoHelix-4: 38 genes - ctDNA panel

Assay uses FOLLOW IT® ctDNA Liquid Biopsy Focused Panel Powered by Canexia Health™*

Specimen compatibility: Genomic DNA extracted from fresh blood sample

SNVs, deletions and insertions (up to 24bp): AKT1: E17, ALK: T1151, L1152, C1156, F1174, L1196, L1198, G1202, D1203, S1206, G1269, R1275, Y1278 AR: L702H, V716, S741, W742, Q784, H875, F877, T878, M896 BRAF: Q201, G464, G466, F468, G469, Y472, D594, F595, G596, L597, V600, K601, Ex 15 (V600-M620), G606, CCNE: Amplification, CTNNB1: D32, S33, G34, I35, H36, S37, T41, S45, DDR2: L239, I638, S768, DICER1: D1705-D1709, G1809, D1810-E1813, EGFR: R108, A289, S492, P596, G598, Ex.18, Ex.19, Ex.20, Ex.21, & Amplification, ERBB2: G309, S310, K753, L755, I767, D769, Ex. 20, & Amplification, ESR1: K303, E380, S463, V534, P535, L536, Y537, D538, FGFR1: N546, K656, & Amplification, FGFR2: S252, P253, W290, A315, S372, Y375, C382, N549, K659, E731, E777, & Amplification, FGFR3: R248, S249, G370, S371, Y373, G380, A391, 650, FOXL2: C134, GNA11: Q209, GNAQ: Q209, GNAS: R201, HRAS: G12, G13, Q61, IDH1: R132, IDH2: R140, R172, KIT: S476, Y553, W557 559, V560, L576, K642, V654, T670, D816, D820, N822, Y823, A829, Ex.9, Ex.11, Ex.13, & Amplification, KRAS: K5, A11, G12, G13, L19, Q22, A59, G60, Q61, K117, A146, & Amplification, MAP2K1(MEK1): F53, Q56, K57, K59, V0, D67, I103, I111, C121, N122, P124, P387, MAP2K2(MEK2): F57, Q60, K61, L119, H123, G132, MET: T1010, V1112, H1112, G1181, L1213, D1246, Y1248, Y1253, Ex.13, Ex. 14 (-50 to +25), Ex.18, & Amplification, NRAS: G12, G13, A59, G60, Q61, K117, A146, NTRK1: F589, G595, G667, NTRK3: G623, G696, PDGFRA: R560-E571, P577, N659, D842, L839-Y849, PIK3CA: R88, C90, R93, P104, G106, N107, R108, K111, R115, N345, R357, G364, E365, Ex.6 [start to P377], C420, E453, P539, E542, E545, Q546, D549, E970, E978, M1043, N1044, A1046, H1047, G1049, & Amplification, POLE: Ex.9, Ex.10, Ex.11, Ex.12, Ex.13, Ex.14, (P286R, M295R, S297F, F367S, D368Y, V411L, L424I, M444K, A456P, S459F), PTCH1: W844, G1093, PTEN: A126, G129, R130, R173, R233, K254-K267, RET: G533, K603, C609, C611, C618, C620, C630, D631, C634, G691, E768, L790, Y791 V804, Y806, A886, S904, M918, A919, Ex.10, Ex.13, Ex.15, ROS1: S1986, L2026, G2032, STK11: Q37, P281, TP53: Ex.4, Ex.5, Ex.6, Ex.7, Ex.8, Ex.9; MSI: 21Loci

*OncoHelix-4: FOLLOW IT® ctDNA Liquid Biopsy Focused panel is developed by Canexia Health™. This research use only assay was validated and its performance characteristics were determined by OncoHelix and its partner lab - Hematology Translational Lab. The panel is not approved by Health Canada, as is the case for all cancer genomic panel. Both OncoHelix and HTL laboratories are clinically accredited by CPSA to perform high-complexity molecular testing. Any decisions related to patient care and treatment choices should be based on the independent judgement of the treating physician

Official Partner: